[21] has been used in the semaglutide phase III development program, in which semaglutide showed a gastrointestinal AE profile comparable to that of other GLP-1 receptor agonists [23]
Semaglutide typically does not directly alter hormones that control your menstrual cycle, but rapid weight loss from the medication can trigger temporary changes in period timing, flow, or regularityespecially in the first few months of treatment
It could be due to a formulary change, a need for prior authorization, or even an error
The profiles are fundamentally different: Surgical risks: 1-5% serious complication rate, anesthesia risk, infection, blood clots, staple line leaks (0.5-1%), increased GERD/acid reflux, lifelong nutritional deficiency risk, rare mortality (0.05-0.1%)
having the right medical support can make a significant difference